Sydney, Mar 17, 2008 (ABN Newswire) - Ventracor Limited (ASX: VCR)(ADR: VTCRY) announced today that the US Food and Drug Administration (FDA) has granted unconditional approval for the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).
